Cargando…
Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
OBJECTIVES: To assess the effectiveness of Neuroaspis plp10 nutritional supplement when added to interferon (IFN)-β treatment in patients with relapsing-remitting multiple sclerosis (RRMS). DESIGN: A 30-month phase III multicentre, randomised, double-blind, placebo-controlled trial. Randomisation st...
Autores principales: | Pantzaris, Marios C, Bakirtzis, Christos, Grigoriadis, Nikolaos, Hadjigeorgiou, Georgios, Dardiotis, Efthimos, Loucaides, George, Ntzani, Evangelia, Markozannes, Georgios, Omorfos, Savvas, Valsasina, Paola, Messina, Roberta, Preziosa, Paolo, Rocca, Maria A, Patrikios, Ioannis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639060/ https://www.ncbi.nlm.nih.gov/pubmed/36353267 http://dx.doi.org/10.1136/bmjno-2022-000334 |
Ejemplares similares
-
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial
por: Pantzaris, Marios C, et al.
Publicado: (2013) -
A survey of methodologies on causal inference methods in meta-analyses of randomized controlled trials
por: Markozannes, Georgios, et al.
Publicado: (2021) -
Gene variants of adhesion molecules predispose to MS: A case-control study
por: Dardiotis, Efthimios, et al.
Publicado: (2019) -
Gene variants of adhesion molecules act as modifiers of disease severity in MS
por: Dardiotis, Efthimios, et al.
Publicado: (2017) -
Anti-MOG Positive Bilateral Optic Neuritis and Brainstem Encephalitis Secondary to COVID-19 Infection: A Case Report
por: Tsouris, Zisis, et al.
Publicado: (2022)